Immune Checkpoint Inhibitors to Treat Mesothelioma

Immune Checkpoint Inhibitors to Treat Mesothelioma

A new study supports the use of immune checkpoint inhibitors to treat malignant pleural mesothelioma. The study authors caution that immune checkpoint inhibitors should be used carefully because they can be an expensive treatment. Immunotherapy for Mesothelioma Mesothelioma is a rare type of cancer that is caused by exposure to asbestos. It develops from cells of the mesothelium, the lining that covers many of the internal organs of the body. There are approximately 2,000 cases of mesothelioma diagnosed in the United States every year. Since mesothelioma is so rare, standard treatment options are limited. Standard therapies include chemotherapy, radiation, and surgery. If more than one of these therapies is used, it may be called multimodal therapy. Immunotherapy has emerged in … Continue reading Immune Checkpoint Inhibitors to Treat Mesothelioma »

Immunotherapy as Effective Second-Line Treatment for Mesothelioma

Effective Second-Line Treatment for Mesothelioma

A study from Taiwan has identified an effective second-line treatment for malignant pleural mesothelioma. When a patient is diagnosed with mesothelioma and begins treatment, the first treatment is called the “first-line treatment.” If that treatment does not work or stops working, a “second-line treatment” is given to the patient. For mesothelioma, treatment usually consists of surgery, chemotherapy, and radiation. The exact treatment plan will depend on many factors. Doctors will consider the type of mesothelioma, the condition of the patient, and how much the cancer has spread. A common first-line treatment for mesothelioma patients is chemotherapy with drugs called pemetrexed and cisplatin. When this treatment works properly, it stops cancer cells from growing and multiplying. It is for patients whose … Continue reading Immunotherapy as Effective Second-Line Treatment for Mesothelioma »

Immune Checkpoint Therapy for Mesothelioma

Immune Checkpoint Therapy for Mesothelioma

A new study suggests that immune checkpoint therapy with nivolumab is a promising treatment for a specific type of mesothelioma. The study authors describe three cases of sarcomatoid mesothelioma being treated with nivolumab at Kyoto University Hospital in Japan. A Deadly Form of Mesothelioma There are three types of malignant pleural mesothelioma. They each respond differently to mesothelioma treatments. One of these types is sarcomatoid mesothelioma and it is the rarest type of mesothelioma. Sarcomatoid pleural mesothelioma cells are slender ovals with large or even multiple nuclei. Because these cells are spindle-shaped, this type of mesothelioma is sometimes called spindle-cell mesothelioma. Sarcomatoid mesothelioma is an especially deadly form of the disease. This type grows and spreads faster than the other … Continue reading Immune Checkpoint Therapy for Mesothelioma »

10 New Clinical Practice Guidelines on Immunotherapy for Mesothelioma

10 New Clinical Practice Guidelines on Immunotherapy for Mesothelioma

The Society for Immunotherapy of Cancer (SITC) organized a multidisciplinary panel of experts to develop new clinical practice guidelines on the use of immunotherapy in mesothelioma treatment. Immunotherapy is a type of cancer treatment. It uses the patient’s immune system to fight cancer. Immunotherapy has changed lung cancer care in recent years. It can help some patients survive longer. There is a new type of immune treatment called Immune checkpoint inhibitors (ICIs). ICI’s are used to treat patients with mesothelioma. The use of ICIs to treat mesothelioma tumors has quickly become part of clinical practice. Immune checkpoint inhibitors block mesothelioma’s natural resistance to immune system Challenges remain on how to identify patients who might benefit from ICIs. A panel of … Continue reading 10 New Clinical Practice Guidelines on Immunotherapy for Mesothelioma »

A Bright Future for Immune Checkpoint Inhibitors in Mesothelioma Treatment

A Bright Future for Immune Checkpoint Inhibitors in Mesothelioma Treatment

A new report shows that immune checkpoint inhibitors can be a practical and rational therapeutic approach to treating mesothelioma patients. The use of ICIs to treat human tumors has quickly become part of clinical practice. Immune checkpoint inhibitors block mesothelioma’s natural resistance to immune system attack. They are among the most promising approaches to combating this intractable cancer. Researchers from the Cellular and Molecular Research Center report the use of ICIs in tumor immunotherapy. What is Tumor Immunotherapy? Malignant mesothelioma is a frustrating disease for patients and doctors. Conventional cancer treatments often do not work. If cancer recurs, doctors can try other approved treatments, even if they are not part of the official treatment guidelines. Immunotherapy is also referred to … Continue reading A Bright Future for Immune Checkpoint Inhibitors in Mesothelioma Treatment »

Adoptive Cell Therapy and Interventional Oncology in Mesothelioma

Adoptive Cell Therapy in Mesothelioma

New data suggests that adoptive cell therapy is a powerful, targeted way to treat malignant pleural mesothelioma. Pleural mesothelioma is a deadly cancer of the lining around the lungs. It is caused by asbestos exposure and is notoriously difficult to treat. Now, a new study suggests that cell therapy may help mesothelioma drug treatments work even better. What is Adoptive Cell Therapy? Adoptive cell therapy is a form of immunotherapy. Immunotherapy treatments harness the immune system to help fight cancer. Immunotherapy works alone or in combination with other treatments like chemotherapy or surgery. Many researchers and doctors believe that immunotherapy is the future of mesothelioma treatment. This therapy is a more targeted way to deliver these cancer-fighting drugs. It does … Continue reading Adoptive Cell Therapy and Interventional Oncology in Mesothelioma »

Understanding CAR T-Cell Therapy in Malignant Mesothelioma

Understanding CAR T-Cell Therapy in Malignant Pleural and Peritoneal Mesothelioma

One of the new therapies for mesothelioma is called antigen receptor T-cell therapy. It gives promise to malignant mesothelioma patients. This unique therapy has recently shown that it works in phase I clinical trials. A new report from French scientists details the current state of this therapy. This therapy has only been tested in a highly selected patient population. And it requires highly complex engineering. Yet, the treatment therapy shows promise. Adapting CAR T-Cell Therapy to Mesothelioma Malignant pleural and peritoneal mesothelioma are rare and aggressive cancers. They have had limited treatment options with moderate survival benefits. And all treatments have an impaired quality of life for a very long period. A chemotherapy drug combination known as cisplatin–pemetrexed has been … Continue reading Understanding CAR T-Cell Therapy in Malignant Mesothelioma »

Maximizes Your Immune Cell Response with High-Intensity Exercise

High-Intensity Exercise Maximizes Immune Cell Response

There is an increasing role of high-intensity exercise training in cancer care. Evidence suggests that exercise can reduce side effects of treatment. And it has the added benefits of improving physical functioning and quality of life. Exercise leads to an increase of adrenalin, which also triggers a patient’s natural immune response. This can alter the tumor microenvironment and lead to reduced tumor growth. New data suggest that exercise could improve immune responses against cancer cells. It works by increasing immune cell infiltration to the tumor. And it may have an impact on disease progression. A new clinical trial has been initiated. It will investigate if high-intensity exercise can benefit patients with lung cancer. Can adrenalin mobilize and increase the infiltration … Continue reading Maximizes Your Immune Cell Response with High-Intensity Exercise »

Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab

Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab

Canadian researchers say radiotherapy may hold the key to improving outcomes in mesothelioma. Mesothelioma is a fast-growing membrane cancer caused by asbestos. Doctors have not found a single therapy that can beat it. For most patients, a combination of treatments offer the best survival odds. Pembrolizumab plus Radiotherapy Pleural mesothelioma is a rare lung-related cancer caused by asbestos exposure. There is no cure for mesothelioma. Most mesothelioma patients have a combination of therapies. Radiation is one of the methods doctors use to help slow its spread. Outcomes in mesothelioma vary widely with the use of radiotherapy. Pembrolizumab is used in combination with chemotherapy as a first-line treatment for mesothelioma. Radiotherapy uses beams of intense energy to kill cancer cells. One … Continue reading Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab »

First-Line Chemotherapy versus Immunotherapy versus Maintenance Therapy

Chemotherapy versus Immunotherapy versus Maintenance Therapy

A recent study compared mesothelioma patients’ survival by physician’s choice of treatment. Is first-line chemotherapy the best choice? Malignant pleural mesothelioma is an aggressive cancer that affects older adults. Mesothelioma patients often have other comorbidities making real-world treatment decisions challenging. The first was by choice of first-line chemotherapy. The second was the physician’s choice of second-line chemotherapy versus immunotherapy. And the third was by the physician’s choice of use of maintenance therapy. Physician’s Choice of First-Line Chemotherapy Drugs This is the largest real-world study of U.S. patients diagnosed with mesothelioma. Scientists analyzed physicians’ choice of first-line chemotherapy, second-line therapy, and maintenance therapy. In the first-line chemotherapy analysis, there was no significant difference in patient survival. As of this writing, the only … Continue reading First-Line Chemotherapy versus Immunotherapy versus Maintenance Therapy »

Get your free copy of
“Surviving Mesothelioma” Today!